There’s a Blood Test for Alzheimer’s. Should You Get One? 7 Things to Know First

Until recently, finding out whether Alzheimer’s-related changes were present in the brain meant an expensive amyloid PET scan or a spinal tap. Amyloid plaques, the hallmark of the disease, were long confirmed only through those methods. Now a simple blood draw can help answer that question, and the FDA has cleared four blood-based biomarker tests for Alzheimer’s disease. rutgersalz

But just because we can test, should we? The answer depends on who is tested, which test is used, and what the results mean for their care.

1. What the tests measure

Alzheimer’s is associated with a buildup of two proteins in the brain, amyloid-beta and tau. Blood tests look for markers of these, such as the amyloid-beta ratio (Aβ42/Aβ40) or phosphorylated tau (p-tau217 and p-tau181). They offer biological evidence of Alzheimer’s-related changes. They don’t show how well someone is thinking, when symptoms will begin, or how quickly abilities may change.

2. Not all tests are created equal

Tests differ in what they measure, how they’re run, and how accurate they are. Fujirebio’s Lumipulse was cleared in May 2025 and Roche’s pTau181 in October 2025, followed by C2N’s PrecivityAD2 and Roche’s Elecsys pTau217 in August 2026. They also do different jobs: the pTau217 test supports both ruling in and ruling out amyloid pathology, while pTau181 is designed mainly to help primary care physicians rule it out. FDA Clears Fourth New Blood Test to Diagnose Alzheimer’s - BHI +3

The Alzheimer’s Association guideline notes significant variability in accuracy and warns that patients and clinicians may wrongly assume the tests are interchangeable. For specialized memory care, it sets thresholds: at least 90% sensitivity and 75% specificity to triage, and 90% on both to substitute for PET or spinal fluid testing. Tests ordered directly by consumers are criticized by groups including the Alzheimer’s Association, partly because consumer-initiated testing is largely unregulated. new clinical guidelines recommend use of blood tests instead of brain scans for alzheimers diagnosis +2

3. A positive result isn’t a dementia diagnosis

With a high-sensitivity test, a negative result rules out Alzheimer’s pathology with high probability, which points toward looking for other causes of memory changes. A positive result suggests Alzheimer’s-related changes are present, but these tests aren’t designed to give a definitive diagnosis, and positive results from triage tests need confirmation with amyloid PET or spinal fluid analysis. kyodonewsprwire.jp +2

Alzheimer’s-related changes can begin years before symptoms, so a result is one piece of a bigger picture that includes symptoms, cognitive assessment, medical history, and daily functioning. A negative result doesn’t mean memory concerns should be ignored, either, because other conditions can affect thinking.

4. Should you test without symptoms?

Interest is high: 90% of Americans say they would take a blood biomarker test for Alzheimer’s even without symptoms. But practice hasn’t caught up. The newest test is cleared for people 55 and older with signs, symptoms, or complaints of cognitive decline, and one expert notes that without a disease-modifying therapy for people without symptoms, a physician would not currently change guidance based on a level alone. Some experts compare it to how high cholesterol relates to heart attack risk: a risk signal, not a certainty. At-Home Alzheimer’s Testing Is Here: Are Physicians Ready? +3

5. Could the result change treatment?

Potentially. Two FDA-approved anti-amyloid medications, lecanemab and donanemab, have been shown in clinical trials to slow memory decline and help maintain independence in early-stage Alzheimer’s. But eligibility requires early symptomatic disease, confirmed amyloid, and safety checks such as a pre-treatment MRI, and they are not a cure. Alzheimer Therapeutics Program +2

6. What else to consider

• Other health conditions. Kidney disease can skew results. omanobserver
• Representation. Researchers are still studying how well tests perform across ages, racial and ethnic groups, and care settings.
• The emotional side. Some people without memory problems who’ve been tested describe worrying over every forgotten name or misplaced key. Think about who you’d lean on. omanobserver
• The practical side. Experts note that federal genetic discrimination law doesn’t extend to disability or long-term care insurance, and consumer-ordered tests may fall outside general health privacy protections. That’s not a reason to avoid testing when you have symptoms and need answers, but it’s worth thinking about timing if you’re considering long-term care coverage. beingpatientbeingpatient

7. Seven questions to ask first

1. Why am I considering testing?
2. Which test do you recommend, and how accurate is it for someone like me?
3. Has it been validated for people with my symptoms, age, and health?
4. What would a positive, negative, or uncertain result mean, and what happens next?
5. Would the result change my care or planning?
6. What are the downsides, including emotional, financial, privacy, and insurance effects? If I’m considering long-term care coverage, should I speak with an advisor first?
7. Who will explain the results and help me decide what to do next?

The bigger picture: lifestyle matters, before and after a diagnosis

A test result, or even a diagnosis, isn’t the end of what you can do. The 2024 Lancet Commission estimated that around 45% of dementia cases are potentially preventable by addressing 14 modifiable risk factors, including hearing impairment, vision loss, high blood pressure, physical inactivity, depression, and social isolation. ophthalmologytimesdementia

And lifestyle may matter after diagnosis, too. A 2024 randomized trial led by Dean Ornish and co-authored by Harvard’s Rudolph Tanzi tested an intensive program of diet, exercise, stress reduction, and social interaction. It enrolled 51 people with mild cognitive impairment or early dementia due to Alzheimer’s, and after 20 weeks the groups differed significantly on three measures of cognition and function, with a borderline difference on a fourth. It was small and early-phase, and Tanzi himself cautioned against overinterpreting it. healthdayharvard

The takeaway isn’t that lifestyle is a cure or a substitute for medical evaluation and treatment. It’s that “there’s nothing we can do” isn’t true. Movement, nourishing food, stress management, connection, and purpose are things a person can work on at any stage, alongside medical care.

At TheKey, our Balanced Care Method® brings this whole-person thinking into everyday life. We can’t replicate a research protocol, but we can help older adults, including people living with cognitive change, build movement, nourishment, connection, cognitive engagement, joy and purpose, and sleep into their routines.

The best question isn’t “Can I get tested?” It’s “What would knowing mean for me, and what would I do with that information?”

If you’re concerned about changes in memory or thinking, start with your healthcare professional. For support with daily routines, cognitive engagement, and personalized care at home, connect with TheKey’s local care team.

This article is educational and not medical advice. Talk with your health care provider about whether testing is right for you.

Sources: Alzheimer’s Association, clinical practice guideline (2025) and FDA clearance statement (August 2026); Roche; CNN; AARP; NeurologyLive; The Lancet Standing Commission on Dementia (2024); Ornish et al., Alzheimer’s Research & Therapy (2024); Being Patient.